Daily Stock Analysis, BCRX, BioCryst Pharmaceuticals Inc, priceseries

BioCryst Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
5.88
Close
5.60
High
5.92
Low
5.58
Previous Close
5.86
Daily Price Gain
-0.26
YTD High
7.30
YTD High Date
Jan 9, 2017
YTD Low
5.34
YTD Low Date
Feb 7, 2017
YTD Price Change
-0.76
YTD Gain
-11.95%
52 Week High
7.56
52 Week High Date
Dec 19, 2016
52 Week Low
1.74
52 Week Low Date
Feb 24, 2016
52 Week Price Change
3.70
52 Week Gain
194.74%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 23. 2014
11.07
Jan 12. 2015
12.03
12 Trading Days
8.69%
Link
LONG
Mar 31. 2015
9.03
Apr 27. 2015
10.01
18 Trading Days
10.90%
Link
LONG
May 14. 2015
10.55
Jun 15. 2015
12.28
21 Trading Days
16.39%
Link
LONG
Jun 16. 2015
12.65
Jul 22. 2015
15.84
25 Trading Days
25.18%
Link
LONG
Sep 4. 2015
11.52
Sep 21. 2015
12.59
10 Trading Days
9.26%
Link
LONG
Apr 13. 2016
2.89
Apr 29. 2016
3.17
12 Trading Days
9.67%
Link
LONG
Jul 27. 2016
3.41
Aug 16. 2016
4.41
14 Trading Days
29.27%
Link
LONG
Nov 7. 2016
4.49
Nov 28. 2016
5.74
14 Trading Days
27.81%
Link
Company Information
Stock Symbol
BCRX
Exchange
NasdaqGS
Company URL
http://www.biocryst.com
Company Phone
919-859-1302
CEO
Jon P. Stonehouse
Headquarters
North Carolina
Business Address
4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC 27703
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000882796
About

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II/III clinical trial for hereditary angioedema (HAE); BCX7353, an oral serine protease inhibitor, which is in Phase II clinical trial for HAE; and other second generation HAE compounds, an oral serine protease inhibitor, which is in preclinical stage. The company's product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in preparation to file for regulatory approval. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; and Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.